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I/II trial to determine the safety and efﬁcacy of a combination of
arsenic trioxide, melphalan and ascorbic acid (AA) as preparative
regimen in patients undergoing high-dose therapy (HDT) and autol-
ogous hematopoietic progenitor cell transplantation for multiple my-
eloma (MM). We also assessed the impact ATO levels on melphalan
pharmacokinetics (PK), engraftment and toxicity.
Methods: Forty-eight patients with secretory myeloma (23 females,
25 males; median age: 54, range: 35-70) were treated between 4/04
and 8/05. All patient received melphalan 100 mg/m2 IV on days -4
and -3 and AA 1000 mg/day IV on days -9 to -3. Patients were
randomized to 3 arms; no ATO (arm 1), ATO 0.15 mg/kg IV on days
-9 to -3 (arm 2) and ATO 0.25 mg/kg IV on days -9 to -3 (arm 3).
Twelve patients had a prior autograft. Median CD34 cells dose in-
fused was 4.5  106/kg (range 2.3 -10.9).
Results: Patients in all 3 arms were evenly matched.With a median
F/U of 17 months (range 6-29) post autograft, no dose-limiting
toxicity or non-relapse mortality was seen. Toxicity was limited to
grade I or II nausea, vomiting and diarrhea and was similar in all 3
arms. Melphalan PK was not altered by ATO pretreatment. Median
time to neutrophil engraftment (ANC 500/ dl) was 9 days, with no
engraftment failures or delays in the ATO arms. CR rate for the entire
group was 23%, and overall response rate (ORRCR  PR) was
75%. Progression-free survival (PFS) and overall survival (OS) after
17-month F/U were 68% and 82%, respectively. There was no
signiﬁcant difference in CR, ORR, PFS or OS between the 3 arms (p
 0.9, 0.9, 0.5 and 0.6, respectively). A prior autologous transplant (p
 0.02) and abnormal cytogenetics at transplant (p  0.04) were
associated with a signiﬁcantly shorter remission.
Conclusions: ATO  melphalan  ascorbic acid is a safe,
effective and well tolerated preparative regimen for patients with
multiple myeloma undergoing an autotransplant. A prior autograft
and abnormal cytogenetics are associated with worse outcome.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY PA-
TIENTS WITH MULTIPLE MYELOMA
Qazilbash, M.H.1, Gul, Z.2, Jindani, S.2, Saliba, R.1, Hosing, C.1,
Mendoza, F.1, Qureshi, S.P.1, Weber, D.M.1, Wang, M.1, Flosser, T.1,
Couriel, D.P.1, De Lima, M.1, Kebriaei, P.1, Popat, U.1, Alousi, A.M.1,
Champlin, R.E.1, Giralt, S.A.1 1UT-MD Anderson Cancer Center,
Houston, TX; 2Wayne State University/ Detroit Medical Center (Grace
Program), Detroit, MI.
Background: Several trials have shown that autologous stem cell
transplantation is superior to conventional therapy in terms of
complete response (CR) rate, event-free survival (EFS) and overall
survival (OS). This treatment, however, is generally limited to
patients younger than 65 due to concerns about excessive toxicity
and treatment-related mortality (TRM) in older patients. Previous
reports have shown that age alone should not exclude patients from
high-dose therapy, as long as they fulﬁll other eligibility criteria. In
this report we analyzed the safety and efﬁcacy of high-dose che-
motherapy (HDT) and autologous transplant in patients with MM
who were  70 years at the time of autotransplant.
Methods: Twenty-six patients (16 males, 10 females) with a
median age of 72 (range 70-79) underwent HDT and an autograft
between July 1999 and October 2005. The preparative regimen
was melphalan 200 mg/m2 in 19 patients (73%), melphalan 180
mg/m2 in 6 and melphalan140 mg/m2 in 1 patient. Of the 26
patients, 12 were receiving ﬁrst remission consolidation, 7 had
primary refractory disease and 7 had relapsed disease. Clonal cy-
togenetic abnormalities were present in 5 patients (19%).
Results: Twenty-two of the 26 patients were alive after a median
follow up of 25 months (range 8-74). Responses (complete 
partial response) were seen in 20 patients (77%), ﬁve (19%) of
which were complete responses. Median PFS was 24 months and
median OS has not been reached yet. 100-day TRM was 0%.
Median times to absolute neutrophil count of 0.5  109/l and
platelets 20  109/l were 10 and 10 days, respectively. Three-
year PFS and OS were 39% and 65%, respectively. A serum
albumin 3.5 g/dl (p0.02), abnormal cytogenetics at transplant
(p0.05) and 2 prior chemotherapy regimens (p0.02) were
associated with a shorter PFS. Patients transplanted with relapsed
disease had a shorter OS (p0.0004). ISS stage, 2 microglobulin
level, lactic dehydrogenase (LDH) level, abnormal cytogenetics,
CCI or HCT-CI at the time of transplant did not emerge as
signiﬁcant predictors of PFS or OS in this group of patients.
Conclusions: HDT and autologous transplant is safe and feasi-
ble in selected patients70 years of age. Patients transplanted with
relapsed disease had a shorter OS.
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TOTAL MARROW IRRADIATION (TMI) USING HELICAL TOMOTHERAPY:
DOSIMETRIC ANALYSIS DEMONSTRATES REDUCED ORGAN DOSES
WHICH CORRELATE WITH REDUCTION IN ACUTE TOXICITIES AND
PREDICT FOR ESCALATION OF DOSE TO TARGET MARROW BEYOND
THAT ACHIEVABLE BY STANDARD TBI
Wong, J.Y.C.1, Liu, A.1, Schultheiss, T.1, Parker, P.1, Krishnan, A.1,
Sahebi, F.1, Karanes, C.1, Spielberger, R.1, Rosenthal, J.1, Forman, S.1,
Somlo, G.1 1City of Hope Cancer Center, Duarte, CA.
TBI dose escalation has been difﬁcult due to associated organ
toxicities. We recently demonstrated the feasibility of using Tomo-
therapy (an image guided IMRT delivery system) to deliver a more
targeted dose of TBI to sites of greatest tumor burden (bone/marrow)
with reduced dose to normal organs in a patient with multiple my-
eloma. This study provides a dosimetric analysis of target bone/
marrow and normal organ doses from the ﬁrst 13 patients treated, and
details of set-up and delivery using this novel system.
Twelve patients with multiple myeloma (MM) were treated with
Mel (200 mg/m2) followed 6 weeks later by TMI as part of a tandem
autologous transplant Phase I/II trial. Total TMI doses were 10 Gy (3
patients), 12 Gy (4 patients), 14 Gy (3 patients) and 16 Gy (2 patients)
delivered 2 Gy QD or BID over 5 days. One patient with AML was
treated with TMITLI to 12 Gy (1.5 Gy BID)  concomitant
Flu/Mel on a separate trial. Treatment time was 50 minutes, jaw size
2.5 cm, and pitch 0.45. Patients were treated supine with full body
immobilization. Whole body CT imaging was performed by the
Tomotherapy unit prior to each fraction to provide 3D alignment of
patient anatomy to the intended target regions.
Median organ doses ranged from 15-65% that of the target bone/
marrow dose. The degree of organ sparing was similar for all patients
despite differences in thickness and habitus. Of the 84 TMI treatment
sessions delivered, only one was temporarily interrupted due to nausea
and vomiting. In the immediate post-TMI period, all MM patients
experienced grade 1-2 nausea, with half experiencing no vomiting.
Erythema, diarrhea, and mucositis were infrequent and grade 1-2.
The AML patient experienced grade 2 nausea, grade 1 vomiting and
grade 3 mucositis. This compares favorably to acute symptoms asso-
ciated with large ﬁeld hemibody RT or standard TBI.
This study conﬁrms the feasibility of using Tomotherapy to deliver
TMI. Dosimetric studies demonstrated reduced organ doses and
predicted for reduced toxicities. Clinical results conﬁrmed these pre-
dictions. The techniques used can be adapted bymost centers with the
technology. This study predicts for the ability to dose escalate to a
level where normal organs receive comparable standard TBI doses
with target regions receiving a signiﬁcantly higher dose than achiev-
able with TBI, offering the potential for improved outcomes in pa-
tients with hematologic malignancies.
GRAFT PROCESSING
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EX-VIVO EXPANSION (EvE) OF PREVIOUSLY CRYOPRESERVED CORD
BLOOD (CB) INTO NATURAL KILLER (NK) CELLS WITH ENHANCED
AML AND NEUROBLASTOMA CYTOTOXICITY: POTENTIAL ROLE OF CB
NK CELLS IN ADOPTIVE CELLULAR IMMUNOTHERAPY (ACI)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Shereck, E.1, Roman, E.1,
Wapner, R.J.2, Cairo, M.S.1,3,4
1
Department of Pediatrics; 2Obstetrics/
Gynecology; 3Medicine; 4Pathology, New York-Presbyterian, Columbia
University.
CD56 NK subsets exhibit differential NK receptors (NKR)
such as cytotoxicity proﬁles including killer-Ig-like receptors
(KIR), C-lectin (NKG2) and natural cytotoxicity receptors (NCR)
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involved with tumor target recognition (Farag et al Blood, 2002). In
particular, AML and Neuroblastoma are NK sensitive pediatric
tumors. CB is limited by the absence of available donor effector
cells (NK, CTL, LAK and NKT cells) for infusion after UCBT
(Cairo et al Transfusion, 2005). We demonstrated the ability to EvE
CB in short-term culture with IL-2, IL-7, IL-12 and anti-CD3
with increased CD3-/16/56dim and bright subsets expressing
KIR3DL1, KIR2DL2, KIR2DL1/S1 and CD94/NKG2a with in-
creased NK and LAK cytotoxicity (Ayello/Cairo et al BBMT,
2006). In this study, we compared short-term culture (48 hrs) with
prolonged cultures (4-10 days) on expansion of NK cells expressing
NCR, KIR, NKG2, lytic ability and mechanisms of tumor lysis.
Rethawed CB cells were cultured 2-10 days with anti-CD3 (50
ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and IL-12 (10 ng/ml)
[ABCY]. NKR expression (KIR2DS4, NKG2D, CD94, NKp46),
intracellular granzyme B and LAMP-1 receptor (CD107a) expres-
sion were determined by ﬂow cytometry. Cytotxcity of EvE effec-
tor CB cells was measured by europium release assay at 20:1 E:T
ratio with tumor targets K562 (NK), Daudi (LAK), Kasumi-1
(AML) and SYSY5Y (neuroblastoma). KIR2DS4 was signiﬁcantly
increased at day 10 vs 2 in ABCY in both CD3-/16/56bright and dim
subsets (16.9	0.4 vs 2.1	0.2% and 22.3	0.3 vs 0.9	0.2%,
p0.001, respectively). C-lectin receptor CD94/NKG2D expres-
sion was increased at day 7 vs 2 (41.4	0.43 vs 23.7	2.0%,
p0.001). NCR expression in CD3-/16/56dim NKp46 subset
was increased at day 7 vs 2 (10.1	0.06 vs 2.62	0.8, p0.001).
Granzyme B expression was increased from day 2 to 10 (25.8	1.7
vs 45.1	1.7%, p0.001). CD107a expression was signiﬁcantly
increased at day 7 vs 2 (12.9 	1.4 vs 69.3	2.2%, p0.001).
Additionally, increased cytotoxicity was demonstrated at day 7 vs 2
with tumor targets K562 (71.5	0.81 vs 53.8	3.9%, p0.001),
Daudi (63.9	0.73 vs 38	1.1%, p0.001), Kasumi-1 (56.6	0.4 vs
31.8	1.8, p0.001) and SYSY5Y (59.5	5.35 vs 32.6	4.9%,
p0.01). In summary, CB MNC may be thawed at time of trans-
plantation, recryopreserved, rethawed at a later date, expanded and
activated up to 10 days to yield viable NK subsets which appear to
be cytolytic against AML and Neuroblastoma and could be poten-
tially used as ACI post UCBT.
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EARLY HEMATOPOIETIC CELLS, INCLUDING MEGAKARYOCYTE PRO-
GENITORS, ARE RECOVERED IN ALDH BRIGHT CELL POPULATIONS
ISOLATED BY CELL SORTING FROM PREVIOUSLY FROZEN UMBILICAL
CORD BLOOD
Deibert, E.1, Gentry, T.1, Foster, S.J.1, Kurtzberg, J.2, Balber, A.E.1
1Aldagen, Inc., Durham, NC; 2Duke University Medical Center,
Durham, NC.
ALDH bright [ALDHbr] cell populations sorted from fresh um-
bilical cord blood [UCB] on the basis of their high aldehyde
dehydrogenase [ALDH] activity are known to include hematopoi-
etic progenitor cells [HPC]. However, neither the hematopoietic
potential of ALDHbr cells recovered from previously frozen UCB,
nor the ability of any ALDHbr cells to generate platelets has been
reported. We have measured hematopoietic [CFC-H] and
megakaryocytic [CFC-M] colony forming cells in ALDHbr and
ALDHdim [depleted of ALDHbr cells] populations from thawed
UCB. Cells were washed, immunomagnetically depleted of cells
expressing glycophorin A and CD14, reacted with ALDE-
FLUOR® for ﬂow cytometric detection of ALDH, and sorted to
yield ALDHbr and ALDHdim populations. ALDHbr cells com-
prised 0.38 	 0.15% [mean 	 SD] of thawed UCB cells. CD34
and CD133 cells comprised 90.9 	 3.1% and 57.7 	 9.4 % of
ALDHbr cells, respectively. CD41 and CD110 cells were 23.4	
11.7% and 1.7 	 3.4 % of the ALDHbr population, respectively.
CFC-H activity was enriched 1116-fold in the ALDHbr population
compared to the ALDHdim population [256 	 104 colonies/1000
cells vs. 0.23 	 0.33 colonies/1000 cells], and 65% of the CHC-H
were recovered in the ALDHbr population. The ratio of erythroid
to myeloid colonies generated from ALDHbr population was 3.7.
Others have shown that most ALDHdim HPCs in fresh UCB are
short term progenitors, whereas earlier long-term culture initiating
cells and cells that establish long-term grafts in NOD-SCID
mouse models are ALDHbr. Consistent with this, we found that
GEMM colonies are about ten times more frequent in ALDHbr
CHC-H [6.6 	 4.5 GEMM /1000 cells] than in ALDHdim [0.6 	
1.2 GEMM/1000 cells] cells from thawed UCB. Furthermore,
CFC-M activity was 2015-fold higher in the ALDHbr population
than the ALDHdim population [60 	 35 colonies/1000 cells vs.
0.03 	 0.02 colonies/1000 cells]. Cells giving rise to large
megakaryocyte colonies, usually considered to be CFC-M with the
most self-renewal potential, were particularly enriched in the AL-
DHbr populations; all the large colonies we detected [38.0 	17.4
large CFC-M/1000 cells] were derived from ALDHbr populations.
The rare CFC-M colonies from ALDHdim cells were small or
non-megakaryocytic. These results suggest that ALDHbr cells re-
covered from thawed, banked UCB could be used to reconstitute
erythroid and myeloid, including megakaryocytic, blood elements
after transplantation.
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PD-1 IS REQUIRED TO INDUCE PERIPHERAL CD8 T CELL TOLERANCE
IN RECIPIENTS OF ALLOGENEIC BONE MARROW TRANSPLANTATION
WITH ANTI-CD154
Haspot, F.1, Fehr, T.1, Hogan, T.1, Honjo, T.2, Sykes, M.1 1BMT/
TBRC, Massachusetts General Hospital, Harvard Medical School, Bos-
ton, MA; 2Department of Immunology and Genomic Medicine, Kyoto
University, Graduate School of Medicine, Yoshida, Kyoto, Japan.
We examined the mechanisms involved in peripheral CD8 T cell
tolerance induced by mixed chimerism achieved with non-myeloa-
blative conditioning with low-dose (3 Gy) total body irradiation
(TBI) and 2mg of anti-CD154 antibody. CD8 T cell tolerance is
CD4 dependent and is characterized by a speciﬁc anergic state
toward donor antigens prior to speciﬁc deletion of donor-reactive
cells. We tested the role of the PD-1 pathway in a model in which
only CD4 peripheral tolerance is required (i.e. TBI 3 Gy and
depleting anti-CD8 mAb Day -1, 2mg of anti-CD154 Day 0
followed by allogeneic BMT) and in a model in which both CD4
and CD8 peripheral tolerance is required (i.e. TBI 3 Gy Day -1
and 2mg of anti-CD154 followed by allogeneic BMT) for the
development of mixed chimerism. PD1-/- (C57BL/6 background)
or C57BL/6 wild-type mice received fully allogeneic bone marrow
cells (B10.A). While WT control mice showed successful mixed
chimerism induction with both regimens, the PD1-/- recipients
failed to develop mixed chimerism unless they were CD8 depleted.
These results indicate that PD1 is required for the tolerance of
peripheral donor-reactive CD8 cells but not for that of CD4 T
cells. We conﬁrmed these results using blocking anti-PD1 and
anti-PD-L1 mAb in WT B6 recipient mice. While control groups
again showed successful engraftment, recipient mice treated with
blocking anti-PD-1 and anti-PDL-1 mAb failed to develop mixed
chimerism unless they were depleted of CD8 cells. Chimeric mice
that were CD8 depleted and received PD-1 blockade accepted
donor skin grafts while rejecting third party grafts. Thus, a func-
tional PD1-PDL1 pathway is critical to achieve donor-speciﬁc
CD8 T cell tolerance in our model.
GVH/GVL
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BLOOD EOSINOPHILIA AS A MARKER OF FAVORABLE OUTCOME AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Aisa, Y.1, Mori, T.1, Nakazato, T.1, Shimizu, T.1, Yamazaki, R.1,
Ikeda, Y.1, Okamoto, S.1 1Keio University Hospital, Tokyo, Japan.
Eosinophilia is observed in a variety of systemic disorders includ-
ing acute and chronic graft-versus-host disease (GVHD) after
allogeneic stem cell transplantation (allo-SCT). The clinical
records of 237 adult patients who underwent allo-SCT were ret-
rospectively reviewed. Peripheral complete blood cell counts
(CBCs) had been performed at least two or three times a week until
day 100 in all cases, and white blood cell differentiation was
Oral Presentations 11
